


RECEIVED  
CENTRAL FAX CENTERAtty Docket No.: R0130D-CON  
USSN: 10/823,012

FEB 26 2008

**Claim Listing**

Claims 1-47 (canceled)

48. (Previously presented) A compound of Formula:




or a pharmaceutically acceptable salt, solvate or a prodrug thereof,  
wherein:

R<sup>1</sup> is methyl; andR<sup>4</sup> is: chloro.

49-51. (Canceled)

52. (Previously presented) The compound *N*-[2-Chloro-4-(4,5-dihydro-1*H*-imidazol-2-ylmethyl)-phenyl]-methanesulfonamide.

53. (Currently amended) A method for producing the compound of claim 48, said method comprising contacting a nitrile compound of the formula:

wherein ~~R<sup>13</sup> is alkyl and~~ R<sup>1</sup> and R<sup>4</sup> are as recited in claim [1] 48;

with ethylene diamine,

to produce the compound of claim [1] 48.

54. (Previously Presented) A composition comprising:

(a) a therapeutically effective amount of a compound of Claim 48; and

Atty Docket No.: R0130D-CON  
USSN: 10/823,012

(b) a pharmaceutically acceptable carrier.

55. (Canceled)

56. (Currently Amended) A method for treating ~~a disease state comprising~~ urinary incontinence ~~by comprising~~ administering to a subject in need ~~of such treatment thereof~~ an effective amount of a Compound of Claim 48.

57. (Currently Amended) The method of Claim 56, wherein the ~~disorder~~ urinary incontinence is stress incontinence.

58. (Currently Amended) The method of Claim 56, wherein the ~~disorder~~ urinary incontinence is urge incontinence.

59-62 (Canceled)